🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Gang An

Fujian Medical University

ORCID: 0000-0003-4922-4614

Also affiliated with Chinese Academy of Medical Sciences & Peking Union Medical College, China Aerospace Science and Technology Corporation, Institute of Hematology & Blood Diseases Hospital

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

4in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 4 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 8 papers. Top paper: “VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo”.

VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo

Blood Cancer Journal(2020)10.1038/s41408-020-00378-z
N/A
0.571DataRank · unranked
44 citations

Bharat K. R. Chaganty, Liang Lin, Lijie Xing, Boopathy Ramakrishnan, Kenneth Wen +18 more

YWHAE/14-3-3ε expression impacts the protein load, contributing to proteasome inhibitor sensitivity in multiple myeloma

Blood(2020)10.1182/blood.2019004147
N/A
0.500DataRank · unranked
27 citations

Mariateresa Fulciniti, Mehmet Samur, Matthew Ho, Shuhui Deng, Lanting Liu +20 more

Dynamic monitoring of circulating tumor DNA reveals outcomes and genomic alterations in patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapy

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2023-008450
N/A
0.457DataRank · unranked
20 citations

Wei Liu, Xiaojuan Wang, Yi Wang, Chunyang Wang, Chen Qiu +13 more

Figure S3 from Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment

10.1158/2767-9764.24092413.v1
N/A
0DataRank · unranked
0 citations

Wenqiang Yan, Huishou Fan, Jingyu Xu, Lingna Li, Chenxing Du +11 more

Ibrutinib alternating with three cycles of interval fludarabine, cyclophosphamide, and rituximab (FCR) in adults with untreated chronic lymphocytic leukaemia as time-limited regimen: a single-arm, multicentre phase 2 trial in China

eClinicalMedicine(2025)10.1016/j.eclinm.2025.103688
N/A
0DataRank · unranked
0 citations

Yuting Yan, Hui Wang, Ying Sun, Xiantao Liu, Rui Lyu +14 more

Data from A Phenogenetic Axis that Modulates Clinical Manifestation and Predicts Treatment Outcome in Primary Myeloid Neoplasms

10.1158/2767-9764.c.6550727.v1
N/A
0DataRank · unranked
0 citations

Yahui Feng, Xiaowen Gong, Yujiao Jia, Qingyan Gao, Xiaokang Jiao +30 more

ERK signaling mediates resistance to immunomodulatory drugs in the bone marrow microenvironment

Science Advances(2021)10.1126/sciadv.abg2697
N/A
0DataRank · unranked
26 citations

Teru Hideshima, Lijie Xing, Su Wang, Wenrong Zhou, Mehmet Samur +15 more

Data from BCMA-Specific ADC MEDI2228 and Daratumumab Induce Synergistic Myeloma Cytotoxicity via IFN-Driven Immune Responses and Enhanced CD38 Expression

(2023)10.1158/1078-0432.c.6530600.v1
N/A
0DataRank · unranked
0 citations

Su Wang, Jiye Liu, Tengteng Yu, Hailin Chen, Kenneth Wen +11 more